Nasal spy mission: can FluMist's inner workings reveal a better flu vaccine?

NCT ID NCT07726862

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study investigates how the immune system inside the nose responds to the FluMist nasal flu vaccine in healthy adults aged 18 to 65. Participants receive a single dose of the vaccine, and researchers collect nasal swabs and gentle saline washes before vaccination and again two and four days later. By analyzing these samples for changes in immune cells, proteins, and viral activity, the study aims to uncover how flu vaccines work at the very site where infection starts—potentially guiding the development of more effective vaccines in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
FluMist (Live Attenuated Influenza Vaccine) given as a nasal spray
What this could lead to
If successful, this research could help scientists design better flu vaccines that work at the site where infection begins.
What could go wrong
This is a very small, early-stage study with only 20 participants, so findings may not apply broadly. There is no direct benefit expected for volunteers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUCOSAL IMMUNE RESPONSE TO INFLUENZA VACCINATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••